
CLYM Stock Forecast & Price Target
CLYM Analyst Ratings
Bulls say
Climb Bio is a promising biotechnology company with a positive outlook due to its pipeline of potential therapeutics for immune-mediated diseases and a favorable safety profile demonstrated by its lead drug candidates, Budoprutug and CLYM116. Additionally, the company's financial outlook is strong, with enough cash to fund operations until 2028 and potential for strong sales of its drugs in multiple indications. However, there are potential financial and competition risks that could impact the company's future performance.
Bears say
Climb Bio is a clinical-stage biotechnology company with a focus on developing therapies for immune-mediated diseases, including Budoprutug for various B-cell mediated diseases and CLYM116 for IgA nephropathy. However, their pipeline drugs have exhibited mixed results in clinical trials, with the efficacy of CLYM116 being unclear and the potential for adverse effects such as immunogenicity remaining unresolved. Additionally, the company's accelerated approval pathway for Budoprutug may not be a guarantee and trial sequencing in China may limit the applicability of results to global markets. Overall, Climb Bio has yet to prove the efficacy and safety of their pipeline drugs, raising concerns about their long-term potential and leading to a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Climb Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
CLYM Analyst Forecast & Price Prediction
Start investing in CLYM
Order type
Buy in
Order amount
Est. shares
0 shares